Biomarkers
By Maimah Karmo
What if your treatment plan could be as unique as your cancer? Biomarker testing makes it possible. Survivor and advocate Maimah Karmo shares how this powerful tool can lead
to life-changing treatment—and why everyone deserves access to it. Read More ›
Biomarkers continue to revolutionize cancer care by providing crucial information for
diagnosis, monitoring, and tailoring treatment plans. Read More ›
Biomarker testing can help your healthcare team select the right treatment for cancer. The American Cancer Society Cancer Action Network is making sure insurance companies will cover it. Read More ›
Let’s talk about BRCA variations and their impact on families. Read More ›
By Wayne Kuznar
Many biologic markers (biomarkers) are known to drive cancer and its progression, allowing scientists to develop new medications to target those biomarkers and increase survival for patients with lung cancer. Read More ›
By Wayne Kuznar
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›
By Dana Taylor
It has become increasingly clear that lung cancer can be caused by different factors, including some environmental chemicals. Lung cancer in never smokers under the microscope. Read More ›
By Dan Dean
Non-Hodgkin lymphoma survivor Dan Dean spoke with several experts about the advances in genomic testing, which have enabled oncologists to treat patients with new “targeted therapies” that fight cancer based on the specific features of a tumor. Read More ›
By Dana Taylor
Two experts discuss the advances made in lung cancer with the introduction of new immunotherapies, which have extended life for patients, and why testing for biomarkers is crucial. Read More ›
In January 2021, the FDA approved a new indication for Xalkori (crizotinib), an oral ALK inhibitor, for the treatment of young patients who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma and ALK mutation. Xalkori was previously approved for metastatic lung cancer and ALK or ROS1 mutation. Read More ›